These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 1578909)

  • 1. Allogeneic versus autologous bone marrow transplantation (BMT) versus intensive consolidation in acute myelogenous leukemia (AML) in first remission. An EORTC-Gimema phase III trial (AML8 A). The EORTC Leukemia Cooperative Group and the GIMEMA Group.
    Zittoun R; Mandelli F; Willemze R; de Witte T; Tura S; Ferrini PR; Stryckmans P; Gattringer C; Petti MC; Solbu G
    Leukemia; 1992; 6 Suppl 2():114-5. PubMed ID: 1578909
    [No Abstract]   [Full Text] [Related]  

  • 2. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
    Zittoun RA; Mandelli F; Willemze R; de Witte T; Labar B; Resegotti L; Leoni F; Damasio E; Visani G; Papa G
    N Engl J Med; 1995 Jan; 332(4):217-23. PubMed ID: 7808487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative value of allogeneic BMT, autologous BMT and intensive chemotherapy during the first complete remission (CR) of acute myelogenous leukemia (AML). An interim analysis of the AML8 EORTC-GIMEMA protocol.
    Zittoun R; Mandelli F; De Witte T; Willemze R; Tura S
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():56-8. PubMed ID: 2202470
    [No Abstract]   [Full Text] [Related]  

  • 4. Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group.
    Zittoun R; Liso V; Mandelli F; Rotoli B; de Witte T; Gattringer C; Resegotti L; Caronia F; Leoni P; Petti MC
    Leukemia; 1992; 6 Suppl 2():76-7. PubMed ID: 1578949
    [No Abstract]   [Full Text] [Related]  

  • 5. Allogeneic versus autologous bone marrow transplantation versus chemotherapy for treatment of acute myeloid leukemia in first complete remission (BGM 84 and BGMT 87 studies). The BGMT Group.
    Reiffers J; Stoppa AM; Rigal-Huguet F; Michallet M; Marit G; Gastaut JA; Attal M; Corront B; Broustet A; Hollard D
    Bone Marrow Transplant; 1991; 7 Suppl 2():36. PubMed ID: 1878709
    [No Abstract]   [Full Text] [Related]  

  • 6. Methodology of evaluation in EORTC trials including BMT in acute myelogenous leukemia (AML) in first complete remission (CR). EORTC Leukemia Cooperative Group (LCG) and GIMEMA.
    Suciu S; Solbu G; Zittoun R; Hayat M; Willemze R; de Witte T; Mandelli F
    Bone Marrow Transplant; 1991; 7 Suppl 2():34. PubMed ID: 1878707
    [No Abstract]   [Full Text] [Related]  

  • 7. [Intensive post-remission therapy in acute myeloid leukemia. Results of a prospective comparative study by the South Germany Hemoblastosis Group].
    Hübner G; Link H; Schönrock-Nabulsi P; Wandt H; Gramatzki M; Löffler B; Fackler-Schwalbe I; Queisser W; Brack N; Geer T; Raab M; Ohl S; Schneider B; Schneider C; Freund M; Poliwoda H; Ehninger G
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():26-32. PubMed ID: 8692115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison between intensive consolidation by bone marrow autograft or by chemotherapy of acute myeloblastic leukemias in 1st complete remission: AML8A protocol of the Leukemia Cooperative Group of the European Organization for Research and Treatment of Cancer (EORTC)].
    Zittoun R; Rio B; Delmer A; Vekhof A; Mandelli F; Willemze R; de Witte T; Tura S; Ferrini PR; Stryckmans P
    Nouv Rev Fr Hematol (1978); 1993 Feb; 35(1):15-6. PubMed ID: 8511034
    [No Abstract]   [Full Text] [Related]  

  • 9. A randomized comparison of post-consolidation therapy in acute non-lymphoid leukaemia: a study of the Italian cooperative group GIMEMA.
    Petti MC; Mandelli F; Vegna ML; Broccia G; Carotenuto M; De Rosa F; Di Marco P; Di Raimondo F; Fioritoni G; Leone G
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():119-20. PubMed ID: 2653486
    [No Abstract]   [Full Text] [Related]  

  • 10. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group.
    Ravindranath Y; Yeager AM; Chang MN; Steuber CP; Krischer J; Graham-Pole J; Carroll A; Inoue S; Camitta B; Weinstein HJ
    N Engl J Med; 1996 May; 334(22):1428-34. PubMed ID: 8618581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group.
    Cassileth PA; Andersen JW; Bennett JM; Harrington DP; Hines JD; Lazarus HM; Mazza JJ; McGlave PP; O'Connell MJ; Paietta E
    Leukemia; 1992; 6 Suppl 2():116-9. PubMed ID: 1578910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission.
    Schiller GJ; Nimer SD; Territo MC; Ho WG; Champlin RE; Gajewski JL
    J Clin Oncol; 1992 Jan; 10(1):41-6. PubMed ID: 1727924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous bone marrow transplantation vs intensive chemotherapy in first complete remission: interim results of GOELAM study in AML.
    Harousseau JL; Pignon B; Dufour P; Ifrah N; Solary E; Abgrall JF; Milpied N; Desablens B; Guyotat D; Herve P
    Leukemia; 1992; 6 Suppl 2():120-3. PubMed ID: 1578912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of bone marrow cells grown in long-term culture for autologous bone marrow transplantation in acute myeloid leukaemia: an update.
    Chang J; Morgenstern GR; Coutinho LH; Scarffe JH; Carr T; Deakin DP; Testa NG; Dexter TM
    Bone Marrow Transplant; 1989 Jan; 4(1):5-9. PubMed ID: 2647188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Childrens Cancer Group pilot study.
    Woods WG; Kobrinsky N; Buckley J; Neudorf S; Sanders J; Miller L; Barnard D; Benjamin D; DeSwarte J; Kalousek D
    J Clin Oncol; 1993 Aug; 11(8):1448-57. PubMed ID: 8336184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group.
    Amadori S; Testi AM; Aricò M; Comelli A; Giuliano M; Madon E; Masera G; Rondelli R; Zanesco L; Mandelli F
    J Clin Oncol; 1993 Jun; 11(6):1046-54. PubMed ID: 8501490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The first results of treatment for adult acute myeloid leukemia according to the AML-01.10 protocol of the Research Group of the Hematology Centers of Russia].
    Parovichnikova EN; Kliasova GA; Sokolov AN; Troitskaia VV; Kokhno AV; Kuz'mina LA; Shaforostova II; Ryzhko VV; Kravchenko SK; Bondarenko SN; Lapin VA; Pristupa AS; Konstantinova TS; Zagoskina TP; Ialykomov IV; Moskov VI; Anchukova LV; Kaporskaia TS; Volodicheva EM; Kaplanov KD; Kondakova EV; Samoĭlova OS; Gavrilova LV; Kulikov SM; Savchenko VG
    Ter Arkh; 2012; 84(7):10-5. PubMed ID: 23038965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapy of acute myeloid leukemia in children--results of the AML II/87 multicenter study].
    Hermann J; Zintl F; Krause M; Palme H; Fuchs D; Prager J; Dörffel W; Domula M; Eggers G; Exadaktylos P
    Kinderarztl Prax; 1991 Nov; 59(11):321-7. PubMed ID: 1758135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).
    Michel G; Leverger G; Leblanc T; Nelken B; Baruchel A; Landman-Parker J; Thuret I; Bergeron C; Bordigoni P; Esperou-Bourdeau H; Perel Y; Vannier JP; Schaison G
    Bone Marrow Transplant; 1996 Feb; 17(2):191-6. PubMed ID: 8640165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
    de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
    Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.